Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus

International Journal of Oncology

Volumn 13, Issue 6, 1998, Pages 1105-1115

  Haas, Claudia ^a   Ertel, Christian ^a   Gerhards, Roswitha ^b   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Costimulation; Hemagglutinin neuraminidase; T lymphocytes; Tumor vaccine

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LARYNX CARCINOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 0031797971     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.6.1105     Document Type: Article

References (45)

1. Henderson RA and Finn OJ: Human tumor antigens are ready to fly. Adv Immunol 62: 217-256, 1996.
2. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P and Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102, 1992.
3. Janeway CH and Bottomly K: Signals and signs for lymphocyte responses. Cell 76: 275-285, 1994.
4. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T and Appelhans B: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 37: 569-577, 1986.
5. Schirrmacher V, Ahlert T, Heicappell R, Appelhans B and von Hoegen P: Successful application of non-oncogenic viruses for anti-metastatic cancer immunotherapy. Cancer Rev 5: 19-49, 1986.
6. Plaksin D, Progador A, Vadai E, Feldman M, Schirrmacher V and Eisenbach L: Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 59: 796-801, 1994.
7. Schirrmacher V and Heicappell R: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific anti-tumor immunity. Clin Exp Metastasis 5: 147-156, 1987.
8. Ahlert T, Sauerbrei W, Baster G, Ruhland S, Bartik B, Simiantonaki N, Schumacher I, Häcker B, Schumacher M and Schirrmacher V: Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J Clin Oncol 15: 1354-1366, 1997.
9. Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R and Hagmüller E: Immunization with virus modified tumor cells. Semin Oncol (In press).
10. Chambers P, Millar NS, Binningham RW and Emmerson PT: Molecular cloning of complementary DNA to Newcastle disease virus and nucleotide sequence analysis of the junction between the genes encoding the hemagglutinin-neuraminidase and the large protein. J Gen Virol 67: 475-486, 1986.
11. Umansky V, Shatrov VA, Lehmann V and Schirrmacher V: Induction of nitric oxide synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-κB. Int Immunol 8: 491-498, 1996.
12. Von Hoegen P, Zawatzky R and Schirrmaclier V: Modification of tumor cells by a low dose of Newcastle disease virus: III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon alpha, beta. Cell Immunol 126: 80-90, 1990.
13. Lorence RM, Rood PA and Kelley KW: Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 80: 1305-1312, 1988.
14. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Therapy (In press).
15. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide specific cytotoxic T cell responses. Eur J Immunol 23: 2592-2596, 1993.
16. Schirrmacher V, Haas C, Bonifer R and Ertel C: Virus potentiation of tumor vaccine T cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 3: 1135-1148, 1997.
17. Suzuki Y, Suzuki T, Matsunaga M and Matsumoto M: Gangliosides as paramyxovirus receptor. Structural requirement of sialooligosaccharides in receptors for hemagglutinating virus of Japan (Sendai virus) and Newcastle disease virus. J Biochem 97: 1189-1199, 1985.
18. Schirrmacher V, Beckhove P, Krüger A, Rocha M, Umansky V, Fichtner KP, Hull WE, Zangemeister-Wittke U, Griesbach A, Jurianz K and von Hoegen P: Effective immune rejection of advanced metastasized cancer. Int J Oncol 6: 505-521, 1995.
19. Russell PH and Alexander DJ: Antigenic variation of Newcastle Disease Virus strains detected by monoclonal antibodies. Arch Virol 75: 243-253, 1983.
20. Iorio RM, Lawton KA, Nicholson PM and Bratt MA: Monoclonal antibodies identify a strain-specific epitope on the HN glycoprotein of Newcastle disease virus strain Australia-Victoria. Virus Res 1: 513-525, 1984.
21. Smith GW and Hightower LE: Revertant analysis of a temperature-sensitive mutant of Newcastle disease virus with defective glycoproteins: implication of the fusion glycoprotein in cell killing and isolation of a neuraminidase-deficient hemagglutinating virus. J Virol 42: 659-668, 1982.
22. + thymocytes. Nature 330: 170-173, 1987.
23. Iorio R, Borgmann JB, Glickman RL and Bratt MA: Genetic variation within a neutralizing domain on the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. J Gen Virol 67: 1393-1403, 1986.
24. June CH, Ledbetter JA, Linsley PS and Thompson CB: Role of the CD28 receptor in T cell activation. Immunol Today 11: 211-216, 1990.
25. Chen L, Linsley PS and Hellström KE: Costimulation of T cells for tumor immunity. Immunol Today 14: 483-486, 1993.
26. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H and Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415, 1995.
27. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA and Pleogh HL: Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA 93: 11327-11333, 1996.
28. Ploegh HL: Viral strategies of immune evasion. Science 280: 248-253, 1998.
29. Chen F, Zou JZ, Di Renzo L, Winberg G, Hu LF, Klein G and Ernberg I: A subpopulation of latently EBV-infected normal B cells resemble Burkitt lymphoma (BL) cell in expressing EBNA1 but not EBNA2 or LMP1. J Virol 69: 3752-3758, 1995.
30. Iezzi G, Karjalaincn K and Lanzavccchia A: The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8: 89-95, 1998.
31. Glinsky GV: Cell adhesion and metastasis: is the site specificity of cancer metastasis determined by leukocyte-endothelial cell recognition and adhesion? Clin Rev Int Oncol/Hematol 14: 229-278, 1993.
32. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356, 1990.
33. Springer TA: Adhesion receptors of the immune system. Nature 346: 425-434, 1990.
34. Dustin MI and Springer TA: T cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341: 619-623, 1989.
35. Bachmann MF, McKall-Faienza K, Schmits R, Bouchard D, Beach J, Speiser DE, Mak TW and Ohashi PS: Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7: 549-557, 1997.
36. Croft M, Bradley LM and Swain SL: Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 152: 2675-2685, 1994.
37. Sprent J: Immunological memory. Curr Opin Immunol 9: 371-379, 1997.
38. Lenschovv DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258, 1996.
39. Schirrmacher V and von Hoegen P: Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res 2: 183-196, 1993.
40. Schirrmachcr V, Griesbach A and Zangemeister U: Gamma-irradiated viable tumor cells as whole cell vaccines can stimulate in situ syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. Vaccine Res 3: 31-48, 1994.
41. Schild HJ, von Hoegen P and Schirrmacher V: Modification of tumor cells by a low dose of Newcastle Disease Virus. II. Augmented tumor specific T cell response as a result of CD4 and CD8 immune T cell cooperation. Cancer Immunol Immunother 28: 22-28, 1988.
42. Von Hoegen P, Weber E and Schirrmacher V: Modification of tumor cells by a low dose of Newcastle Disease Virus: augmentation of the tumor specific T cell response in the absence of an anti-viral response. Eur J Immunol 18: 1159-1166, 1988.
43. Stein R, Chen S, Grossman W and Goldenberg DM: Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen. Cancer Res 49: 32-43, 1989.
44. Sethi KK and Brandis H: Synergistic cytotoxic effect of macrophages and normal mouse serum on neuraminidase-treated murine leukaemia cells. Eur J Cancer 9: 809-819, 1973.
45. Novogrodsky A, Suthantiran M, Saltz B, Newman D, Rubin AL and Stenzel KH: Generation of a lymphocyte growth factor by treatment of human cells with neuraminidase and galactose oxidase. J Exp Med 151: 755-762, 1980.